The 2025 edition will take place on October 9, 10 and 11, 2025.
Page contents
Public
This training program is addressed to regulatory officers, patent attorneys and in-house lawyers, as well as public servants working in public health organizations, who must navigate through the several legal domains of relevance in pharmaceutical research, development and innovation.
Teaching language: English
Programme
CEIPI has been offering since 2019, in Strasbourg, an advanced training program, a unique educational proposal targeting regulatory and intellectual property professionals in the pharmaceutical sector. The three days of training have revolved around the interface between patent law, supplementary protection certificates and regulatory data protection.
The development, authorisation and commercialisation of medicinal products in the pharmaceutical sector are amongst the most regulated and complex areas of European Union (EU) law. The legal framework governing the regulation of medicinal products can affect a broad range of private rights, intellectual property law, competition law and consumer law. In particular, patents, supplementary protection certificates (SPCs) and regulatory rewards, notably regulatory data protection, constitute a sophisticated legal framework of overlapping exclusivities that influences both innovation and competition. This complexity creates challenges for experts tasked with understanding a rapidly evolving legal and regulatory landscape.
The CEIPI Advanced Training Program on Regulatory Affairs and Intellectual Property Protection in the Pharmaceutical Industry, now in its fifth edition, is a unique educational proposal targeting regulatory and intellectual property professionals in the pharmaceutical sector. The three days of intensive training revolve around the intersections of patent and regulatory law. In this respect, leading legal professionals and experts in the field will teach issues such as SPCs and regulatory data protection, amongst other relevant topics.
This interactive course aims to provide an up-to-date overview of the European pharmaceutical regulatory environment, procedures and obligations as well as on the patent and SPC related landscape. It will create a space for discussion on how to interpret and apply legislation in this sector in light of new developments. These developments include an overview of the current state of the European Commission’s proposals for the revision of the EU pharmaceutical legislation and of the SPC legislation.
The program for the 2025 edition will be available shortly.
Type of training and certification
A certificate of completion shall be delivered upon full attendance of the participant to the training.
Registration fees and Enrolment
Professionals:
- 1 685 € TTC (early bird) before July 20 2025.
- 1 850 € TTC (full price) for all registrations after July 20 2025.
Students:
- 525 € TTC * (initial training)
*subject to validation by the university authorities
Candidates must complete an online pre-registration form: https://sondagesv3.unistra.fr/index.php/195561?lang=en
Duration
The program has a total duration of 18 hours, distributed in three days.
Timetable
The seminar takes place between 9am and 6pm on weekdays, and between 9am and 1pm on Saturdays.
These times are indicative and subject to change.
Location
On site in Strasbourg as well as remotely.
Heads of studies
The program is jointly designed and directed by:
- Peter Thomsen, Senior Patent Counsel IP Policy & Litigation, Novartis International AG
- Alexander Meier, VP, Head, Legal Regulatory Strategy and Global Regulatory Policy at Moderna
- Pierick Rousseau, Former Intellectual Property Director at Pierre Fabre
- Thomas Lemieux, Lecturer at CEIPI